Mitochondrial peptide signalling.
Mitochondria-derived and mitochondria-targeted peptides in metabolism and stress responses.
Mitochondria are not only the site of oxidative phosphorylation; they are also signalling organelles that communicate their status to the rest of the cell and, through circulating factors, to the rest of the body. Two distinct classes of peptide are grouped here, and the distinction matters because they are quite different things. The first class is peptides encoded within mitochondrial DNA itself, in short open reading frames inside genes normally read as ribosomal RNA. These are genuinely mitochondria-derived and act as signalling molecules. One has been described as a stress-responsive regulator that activates the AMP-activated protein kinase energy-sensing pathway, influences folate and methionine one-carbon metabolism, and under metabolic stress translocates to the cell nucleus where it is proposed to help direct adaptive antioxidant gene expression. Another acts both inside and outside the cell: intracellularly it binds and antagonises pro-apoptotic Bcl-2 family proteins, preventing their translocation to mitochondria and suppressing programmed cell death, and extracellularly it signals through a cytokine-like receptor complex that activates STAT3 and engages formyl peptide receptors. It also interacts with insulin and IGF-1 signalling. Circulating levels of both have been described as declining with age, which is the observation driving interest in them. The second class is not mitochondria-derived but mitochondria-targeted by design. A peptide with an alternating aromatic and cationic motif carries a net positive charge that drives selective accumulation in the inner mitochondrial membrane, where it binds reversibly to cardiolipin, an anionic phospholipid found almost exclusively there. By associating with cardiolipin it is proposed to stabilise cristae architecture, protect the interaction between cardiolipin and cytochrome c, and support electron-transport-chain organisation and membrane potential. This is a structural stabilisation mechanism rather than a receptor-mediated signal, and it is why the compound is described as improving mitochondrial efficiency rather than stimulating it. Honest assessment: this is an active and legitimate research field with well-characterised molecular interactions, but the characterisation is predominantly in cell and animal systems. Human clinical evidence is limited, and the mitochondria-targeted compound has been through clinical trials in specific conditions without producing a clearly positive result in every setting. None of these is an approved medicine, and none should be described as an established treatment for age-related decline or metabolic disease.
Peptides acting through this pathway.
FAQ.
What does mitochondrial peptide signalling do?
Mitochondria are not only the site of oxidative phosphorylation; they are also signalling organelles that communicate their status to the rest of the cell and, through circulating factors, to the rest of the body. Two distinct classes of peptide are grouped here, and the distinction matters because they are quite different things. The first class is peptides encoded within mitochondrial DNA itself, in short open reading frames inside genes normally read as ribosomal RNA. These are genuinely mitochondria-derived and act as signalling molecules. One has been described as a stress-responsive regulator that activates the AMP-activated protein kinase energy-sensing pathway, influences folate and methionine one-carbon metabolism, and under metabolic stress translocates to the cell nucleus where it is proposed to help direct adaptive antioxidant gene expression. Another acts both inside and outside the cell: intracellularly it binds and antagonises pro-apoptotic Bcl-2 family proteins, preventing their translocation to mitochondria and suppressing programmed cell death, and extracellularly it signals through a cytokine-like receptor complex that activates STAT3 and engages formyl peptide receptors. It also interacts with insulin and IGF-1 signalling. Circulating levels of both have been described as declining with age, which is the observation driving interest in them. The second class is not mitochondria-derived but mitochondria-targeted by design. A peptide with an alternating aromatic and cationic motif carries a net positive charge that drives selective accumulation in the inner mitochondrial membrane, where it binds reversibly to cardiolipin, an anionic phospholipid found almost exclusively there. By associating with cardiolipin it is proposed to stabilise cristae architecture, protect the interaction between cardiolipin and cytochrome c, and support electron-transport-chain organisation and membrane potential. This is a structural stabilisation mechanism rather than a receptor-mediated signal, and it is why the compound is described as improving mitochondrial efficiency rather than stimulating it. Honest assessment: this is an active and legitimate research field with well-characterised molecular interactions, but the characterisation is predominantly in cell and animal systems. Human clinical evidence is limited, and the mitochondria-targeted compound has been through clinical trials in specific conditions without producing a clearly positive result in every setting. None of these is an approved medicine, and none should be described as an established treatment for age-related decline or metabolic disease.
Which peptides act through mitochondrial peptide signalling?
MOTS-c, Humanin, SS-31. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit. A plausible pathway is a reason to study a compound, not evidence that it works in humans.